The present invention relates generally to medical devices for implantation within a patient's body.
Since the introduction of the heart rhythm control system—first as an implantable pacemaker in the 1960's, and then as an implantable defibrillator in 1980, implantable electrical stimulating devices have been developed to treat various medical diseases and physiological ailments, such as chronic pain disorders (e.g., nerve injury, failed back syndrome, intractable facial pain, failed neck syndrome, reflex sympathetic dystrophy, thoracic outlet syndrome, and cancer), neurological disorders (e.g., intractable epilepsy and Parkinson's disease), motor disorders (e.g., spasticity, dystonia, spasmodic torticollis, athetosis, head injury, spinal cord injury, stroke, multiple sclerosis, and cerebral palsy), cardiac rhythm disorders (e.g., tachycardia and bradycardia), and psychosomatic disorders (e.g. depression and eating disorders).
Some of these implantable devices are currently being marketed. For example, implantable spinal cord stimulators are currently being used in patients to relieve pain in various parts of the body, e.g., chronic back and leg pain, cancer pain, postoperative spinal cord injury pain, and reflex sympathetic dystrophy pain. The implantation process involves placing leads in the epidural space of the spinal canal in a location that corresponds to the patient's zone of pain. A pulse generator is then implanted in the lower anterior abdominal wall and then connected to electrodes on the leads via an extension that is percutaneously routed from the pulse generator to the leads. Once the system is fully implanted, the pulse generator can then be operated to provide low-voltage electrical stimulation of the spinal cord via the leads.
Another means for managing pain involves implanting micro-current electrical neuromuscular stimulators (MENS) within a patient in the area of the perceived pain. These devices use a very low current (typically 1-100 μA) and operate on a cellular level to speed the healing process, thereby reducing pain. These devices have been specifically used to treat arthritic conditions, sports injuries, low back pain, carpal tunnel, tennis elbow, migraines and other disorders.
A stimulation system similar to the spinal cord stimulator described above is currently being used to treat Parkinson's Disease. In this application, a lead is surgically implanted into the patient's brain adjacent the subthalamic nucleus (STN) or globus pallidus internal (GPi), which control the involuntary movement symptomatic of Parkinson's Disease. A pulse generator is implanted in the patient's chest near the collarbone, and then connected to electrodes on the lead via an extension that percutaneously runs from the pulse generator to the lead. The pulse generator can then be operated to electrically stimulate the effected regions of the brain in order to block the signals that cause the disabling motor symptoms.
Pacemakers are used to alter the heart rate of a patient. A pacemaker, like the previously described devices, includes a pulse generator and leads. The pulse generator is implanted in a sub-dermal pocket in the patient chest, while the leads are inserted into a vein underneath the collar bone and threaded into the heart. Depending on the specific medical problem, a pacemaker can replace the S-A node signals that are delayed or get lost in the electrical pathway between the upper and lower heart. A pacemaker can also maintain a normal timing sequence between the upper and lower heart, and make sure that the critical lower chambers of the heart contract at an adequate rate. A pacemaker can pace a single chamber or two chambers of the right side of the heart, or even synchronize the two ventricles for optimizing the heart pumping capability.
Other electrical stimulating devices might include peripheral nerve stimulators, medical delivery or activation systems, pumps for supporting a failing heart, controlling incontinence, or controlling the opening of a body passage, such as in a shunt for treating hydrocephalus.
All of the above-described devices provide power to the pulse generator in one of two ways: installing a battery within the pulse generator or transmitting wireless energy to the generator, e.g., by wirelessly transmitting power from an external transmitter via radio frequency (RF) telemetry to an internal sub-dermal receiver hard-wired to the pulse generator. In some cases, the pulse generators may be wirelessly controlled by an external command, for example, to obtain data, and/or to activate or otherwise control the pulse generator. For those devices that use a battery, the size of the battery required to support the operational life of the device prevents the pulse generator from being located adjacent the stimulated region. As a result, the pulse generator is usually located in the body remote from electrodes, and a lead must be used to connect the generator and electrodes. For those devices that wirelessly supply power or data to the generator, RF energy may only penetrate a few millimeters into a body, because of the body's dielectric nature. Thus, RF energy may not be able to provide power to, or otherwise communicate with, an implant that is located deep within the body.
Regardless of the means used to supply power to the pulse generator, it is sometimes possible to feel the pulse generator under the skin and visually notice a slight deformity of the skin region that covers the generator. In addition, the requirement of a lead adds complexity to the medical procedure and increases the risk of infection, and in the case of pacemakers and spinal cord stimulators, increases the risk of damaging heart valves that are crossed by the lead or the spinal cord over which the lead is routed. In some cases, the electrodes may become destabilized due to the forces applied on them by the lead. In addition, the leads are typically composed of metal formed as a coil in which electrical current may be adversely induced in the presence of a strong magnetic field, such as that created during Magnetic Resonance Imaging (MRI). As a result, those patients in which these leads are implanted cannot undergo an MRI.
In accordance with a first aspect of the present invention, an implantable stimulator is provided. The implantable stimulator comprises one or more acoustic transducers that are configured to transform acoustic waves into electrical current. The acoustic transducers can comprise any material capable of transforming acoustic energy into electrical energy, but in the preferred embodiment, a piezoelectric material is used. In the preferred embodiment, an array of acoustic transducers are used to maximize the received energy. The implantable stimulator further comprises a stimulating electrode configured to output stimulation energy to adjacent tissue. For example, the tissue can be heart tissue, in which case, the implantable stimulator may be a pacemaker or other cardiac therapeutic device, or the tissue can be nerve tissue, in which case, the implantable stimulator may be a neurostimulator. Other therapeutic devices are also contemplated by the present invention. The stimulation energy is based on the electrical current resulting from the transformation in the acoustic transducers. For example, the energy of the electrical current can be used to generate the stimulation energy and/or signals within the electrical current can be used to define the characteristics of the stimulation energy.
Although the present invention should not be so limited in its broadest aspects, the use of low-frequency acoustic energy (e.g., around 40 KHz) to energize and communicate with the implantable stimulator allows the stimulator to be implanted deep within the tissue of a patient.
In one preferred embodiment, the implantable stimulator comprises an energy storage device configured for storing the electrical current as electrical energy. In this case, the stored electrical energy can be subsequently used to generate stimulation energy under control of the implantable stimulator or another control device. The implantable stimulator may also comprise a switch configured for selectively outputting the electrical energy from the energy storage device to alternately activate and deactivate the implantable stimulator. In this manner, the implantable stimulator can be placed in a “dormant mode” when not in operation in order to conserve energy, and placed in an “active mode” when operated.
In one preferred embodiment, the implantable stimulator comprises control circuitry configured to control the stimulation energy output from the stimulation electrode. For example, the control circuitry can generate and output the stimulation energy or alternately open and close a switch to generate the stimulation energy. Memory can be provided for storing stimulation parameters, which can be used by the control circuitry to control the stimulation energy output from the stimulation electrode.
In another preferred embodiment, the implantable stimulator can be a “dumb device” in that it lacks control circuitry. In this case, the stimulation energy can be generated in response to the electrical current. For example, the electrical current can contain communication signals that alternately open and close a switch in order to generate the stimulation energy. Or the electrical current can be directly transformed into the stimulation energy.
In accordance with a second aspect of the present invention, a self-contained implantable stimulator is provided. The implantable stimulator comprises a casing that integrates the previously described acoustic transducers, stimulator electrode, and control circuitry. In this manner, external leads are not required, since all components necessary to generate the stimulation energy are provided in the casing.
In accordance with a third aspect of the present invention, a stimulation system is provided. The stimulation system comprises a control device configured for transmitting acoustic waves through tissue. The control device can be an external device that can be applied to the skin of the patient or worn by the patient. Or the control device can be an implantable device. In the latter case, the implantable control device may be advantageously charged by an external device using acoustic or radio frequency (RF) energy.
The stimulation system further comprises at least one implantable stimulator configured for transforming the acoustic waves into electrical current, and outputting stimulation energy to adjacent tissue, e.g., heart or nerve tissue. The implantable stimulator(s) can be configured to control the stimulation energy output from the implantable stimulator, in which case, stimulation parameters used to control the stimulation energy can be stored in the implantable stimulator. The controller can alternatively be configured to directly control the stimulation energy output from the implantable stimulator.
In one preferred embodiment, the implantable stimulator(s) is configured for storing the electrical current as electrical energy. The control device may be configured for transmitting other acoustic waves through the tissue to alternately activate and deactivate the implantable stimulator(s). If a plurality of implantable stimulators is provided, each stimulator can be assigned a unique identification code, so that the control device can specifically address the implantable stimulators. For example, the use of unique identification codes may be particularly useful when the timing of the stimulation amongst the implantable stimulators must be coordinated.
In another preferred embodiment, the implantable stimulator(s) is configured for transmitting diagnostic information to the control device, and the control device is configured for controlling the stimulation energy output from the implantable stimulator(s) based on these acoustic waves. For example, if the implantable stimulator(s) is configured for stimulating heart tissue (e.g., in the case of a pacemaker or implantable cardioverter defibrillator (ICD)), the diagnostic information can be pressure information indicative of blood flow, in which case the heart tissue can be stimulated based on this pressure information.
Other objects and features of the present invention will become apparent from consideration of the following description taken in conjunction with the accompanying drawings.
The drawings illustrate the design and utility of preferred embodiment(s) of the present invention, in which similar elements are referred to by common reference numerals. In order to better appreciate the advantages and objects of the present invention, reference should be made to the accompanying drawings that illustrate the preferred embodiment(s). The drawings depict only an embodiment(s) of the invention, and should not be taken as limiting its scope. With this caveat, the preferred embodiment(s) will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
Referring to
The acoustic waves 20 transmitted by the control device 14 have a low frequency (e.g., 40 KHz). As such, the implantable stimulators 12 can be implanted within the deep tissue (such as the heart in this case) of the patient 16 without the need to route and implant leads within the body, thereby avoiding, or at least minimizing, the previously described complications. That is, all of the components necessary to stimulate tissue over the lifetime of the implantable stimulators 12 are contained within the implantable stimulators 12.
The control device 14 is configured to energize the implantable stimulators 12, so that the implantable stimulators 12 may subsequently or immediately output stimulation energy into the heart tissue. Besides energizing the implantable stimulators 12, the control device 14 is also configured to control the operation and configuration of the implantable stimulators 12. For example, the control device 14 may activate and deactivate implantable stimulators 12 (i.e., alternately placing them in an “active mode” and “dormant mode”). The control device 14 may also control the parameters of the stimulation energy (e.g., stimulation intensity, pulse duration, and frequency) output from any of the implantable stimulators 12. Significantly, many cardiac applications require that different regions of the heart be stimulated in a particular sequence and delay between stimulations. For example, the two ventricles of the heart may need to be synchronized to optimize the heart pumping capability. As such, the control device 14 may also control the stimulation sequence and timing of the implantable stimulators 12 to achieve this goal.
The control device 14 can selectively communicate with the implantable stimulators 12 by assigning a unique identification code to each implantable stimulator 12. Thus, the control device 14 can selectively energize or communicate with a specific implantable stimulator 12 by incorporating a corresponding unique identification code into the signal transmitted from the control device 14, or alternatively, by transmitting a predetermined pulse sequence representing the identification code prior to energizing or communicating with the specified implantable stimulator 12. By the same token, a specific implantable stimulator 12 can identify itself to the control device 14 by incorporating its unique identification code into the signal transmitting from the control device 14 or by transmitting a pulse sequence representing the unique identification code.
The stimulating system 10 can be designed in a number of manners. For example, in the preferred embodiment, the control device 14 transmits acoustic energizing waves to an implantable stimulator 14, which transforms the acoustic waves into electrical current that are then stored as electrical energy. The implantable stimulator 12 is designed with control logic, in which case, the control device 14 need only transmit stimulation parameters in the form of acoustic communication waves to program the control logic within the implantable stimulator 12, or alternatively, the implantable stimulator 12 can be preprogrammed with the stimulation parameters. The control logic will then control the stimulation energy output from the implantable stimulator 12 in accordance with these programmed stimulation parameters. For example, the control logic can, itself, generate and output the stimulation energy, or the control logic can alternately open and close a switch that selectively outputs the stored electrical energy as stimulation energy.
As another example, the control device 14 may transmit acoustic energizing waves to the implantable stimulator 12, which are then transformed into electrical energy that is immediately used to generate the stimulation energy. In this case, the control logic transforms the electrical energy into stimulation energy in accordance with stimulation parameters stored in the implantable stimulator 12. As still another example, the control device 14 may transmit acoustic energizing waves in accordance with stimulation parameters stored in the control device 14, in which case, the resulting electrical current in the implantable stimulator 12 are immediately output from the implantable stimulator 12 as stimulation energy. In the later case, the electrical current may be further processed in order to generate stimulation energy that is suitable for the intended therapy. The key here is that no energy storage device is required, since the stimulation energy is immediately output in response to the electrical current.
As still another example, the control device 14 may transmit a series of acoustic communication waves in accordance with stimulation parameters stored in the control device 14. The implantable stimulator 12 transforms the acoustic waves into electrical current that alternately open and close a switch that generates the stimulation energy.
Although the implantable stimulators 12 have been described as pacemakers, it should be appreciated that the implantable stimulators 12 may take the form of any device used to therapeutically stimulate body tissue using electrical energy, e.g., an implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), pain relief nerve stimulator, vagus nerve stimulator, or bladder control stimulator. It should also be appreciated that, although four implantable stimulators 12 are shown, any suitable number of implantable stimulators 12 can be used, including a single implantable stimulator 12.
Referring to
The casing 22 is substantially sealed, and preferably hermetically sealed, to isolate the components of the implantable stimulator 12 from the environment in which the implantable stimulator 10 is to be placed. The casing 22 may include one or more regions that facilitate the passage of acoustic energy through the casing 22. For example, an acoustically transparent panel 30 is suitably mounted over the exposed flat side 24 of the casing 22. Preferably, the panel 30 is a relatively thin wall of titanium or other material, e.g., having a thickness of about one half millimeter (0.5 mm) or less, that may allow the acoustic waves 20 to pass substantially therethrough.
The implantable stimulator 10 further includes an acoustic transducer array 32, a stimulation electrode 34, a reference electrode 36, and a power/communication unit 38. The stimulation electrode 34 is mounted on the pointed region 26 of the casing 22, and the reference electrode 36 is mounted on the flat side 24 of the casing 22. The stimulation electrode 34 is used to electrically stimulate adjacent tissue, and the reference electrode 36 is used as a reference. In the illustrated embodiment, the transducer array 32 comprises four acoustic transducer cells 40 (shown in phantom in
The power/communication unit 38 is coupled to the acoustic transducer array 32 and reference electrode 36 via lead 42 and coupled to the stimulation electrode 34 via lead 44 (shown partially in phantom). The power/communication unit 38 is configured for providing electrical stimulation energy to the stimulation electrode 34 in accordance with stimulation parameters stored within the implantable stimulator 12.
The implantable stimulator 12 may optionally include additional secondary stimulation electrodes (not shown), which may be coupled to the power/communication unit 38 via either separate leads, so that the power/communication unit 38 can independently transmit stimulation energy to the electrodes, or using lead 44, so that the power/communication unit 38 can transmit stimulation energy to the electrodes as a group. The implantable stimulator 12 may optionally include one or more sensors (not shown) capable of measuring physiological parameters, such as temperature, electrical impedance, pressure, position, strain, pH, fluid flow, and the like. As will be described in further detail below, this diagnostic information can be used to control the transmission of stimulation energy. Further details regarding the use of sensors and corresponding componentry is disclosed in U.S. patent application Ser. No. 09/989,912, which is expressly incorporated herein by reference.
Referring still to
The previously described reference electrode 36 is mounted to the outer surface of the piezoelectric layer 50 between the cavities 48. Thus, it can be appreciated that the reference transducer 36 serves as both a common electrode that couples the transducer cells 40 together to provide energizing electrical energy, and a reference point during electrical stimulation of the stimulation electrode 34. Alternatively, a separate common electrode or multiple electrodes (one for each transducer cell 40) can be used to provide the energizing electrical energy to the power/communication unit 38. The acoustic transducer array 32 further comprises four counter electrodes 52 (only two shown in
Thus, it can be appreciated that acoustic waves transmitted to the acoustic transducer array 32 from an external source will cause the piezoelectric layer 50 to vibrate above the cavities 48. As a result, the periodic mechanical strain exerted on the piezoelectric layer 50 generates electrical current at the common electrode 36. Similarly, as electrical current are transmitted to the acoustic transducer array 32 from the power/communication unit 38, an electrical charge will be induced in the piezoelectric layer 50, thereby causing the piezoelectric layer 50 above the cavities 48 to periodically vibrate, resulting in the transmission of acoustic waves.
As best illustrated in
In the illustrated embodiment, the diameter of each cavity 48 is approximately 1.2 mm, which results in a maximum acoustic to electrical energy exchange at a frequency of about 40 KHz-translating to a wavelength of 4 cm in water. Since each transducer cell 40 is much smaller than this wavelength, the performance of the implantable stimulator 12 is not affected by the orientation of the transducer array 32 with respect to the acoustic waves 20 transmitted by the control device 14. Further details regarding the structure and manufacture of acoustic transducer arrays are described in U.S. Pat. No. 6,140,740, which is expressly incorporated herein by reference.
Referring now to
The energy storage device 56 is capable of being charged from an external source (such as the control device 14) using acoustic energy received by the acoustic transducer array 32. The energy storage device 56 may include any of a variety of devices, such as an energy exchanger, a battery, and/or a capacitor. Preferably, the energy storage device 56 is a battery capable of storing electrical energy substantially indefinitely unless actively discharged. In another embodiment, the energy storage device 56 may include both a capacitor and a primary, non-rechargeable battery, although, alternatively, the energy storage device 56 may include a secondary, rechargeable battery and/or capacitor that may be energized before activation or use of the implantable stimulator 12. For example, the energy storage device 56 may include a Lithium thin film battery, such as those available from Oak Ridge Micro-energy Inc. of Salt Lake City, Utah, Infinite Power Supply of Denver, Colo., or Cymber Corporation of Elk River, Minn. Alternatively, the energy storage device 56 may include a standard coin type manganese lithium rechargeable battery, such as those available from Matsushita Battery Industrial Co., Ltd. (MBI) of Osaka, Japan.
The power/communication unit 38 further comprises a controller 58 coupled between the electrodes 34 and 36 for providing electrical stimulation energy to the electrode 34. The controller 58 may include one or more controllers for controlling components of the implantable stimulator 12, timer circuitry (e.g., a clock or counter), reset and threshold circuitry, and/or a processor for generating electrical signals being transmitted by and/or analyzing electrical signals received by the transducer array 32. The controller 58 can be configured using digital signal processors (DSPs), Field Programmable Gate Arrays (FPGAs), Application Specific Integrated Circuit (ASIC)-compatible microprocessors, such as a CoolRISC processor available from Xemics, or other programmable devices, and/or any other hardware components or software modules that may be required for processing, analyzing, storing data, and controlling operation of the implantable stimulator 12.
The power/communication unit 38 further comprises signal detect circuitry 60 coupled to the transducer array 32 for providing a communication channel into the implantable stimulator 12, and specifically, to pass commands and/or information in the acoustic communication waves received by the transducer array 32 for use by the controller 58. For example, the signal detect circuitry 60 may pass commands or other signals to the controller 58, e.g., that acoustic energizing waves have been discontinued, that the implantable stimulator 12 should become operative and/or stimulation parameters. The signal detect circuitry 60 may be a passive FET circuit, thereby drawing substantially no current. The signal detect circuitry 60 may also include a smoothing capacitor (not shown) and/or logic for reducing the sensitivity of the signal detect circuitry 60 to spurious transient signals.
The power/communication unit 38 comprises optional transmission circuitry 62 coupled to the transducer array 32 for providing a communication channel from the implantable stimulator 12, e.g., to pass status information or optional sensor data to the control device 14 as acoustic communication waves. The signals are preferably digital electrical signals, which may be generated, for example, by grounding the counter electrodes 52 (shown in
The power/communication unit 38 comprises memory 64, e.g., volatile or non-volatile memory, including flash memory or ferroelectric memory. The memory 64 may store information, e.g., data received from the optional sensors of the implantable stimulator 12, commands and stimulation parameters for use by the controller 58 to provide stimulation energy to the electrode 34.
The power/communication unit 38 comprises a switch 66 coupled between the energy storage device 56 and the controller 58, such that all or part of the controller 58 may be selectively activated and deactivated under control of the control device 14. Optionally, use of the switch 66 may be foregone, in which case the controller 58 can be directly connected to the energy storage device 56, such that at least some component(s) of the controller 58 may remain active at all times.
The switch 66 can be operated to alternately place the implantable stimulator 12 in an “active mode” or a “dormant mode.” Specifically, to place the implantable stimulator 12 in the active mode, the switch 66 may be closed upon acoustic excitation by an external acoustic energy source, e.g., from the control device 14, to allow current flow from the energy storage device 56 to the controller 58, thereby activating the implantable stimulator 12. To place the implantable stimulator 12 in a “dormant mode,” the switch 66 can may be opened upon acoustic excitation by the control device 14, to prevent current from flowing from the energy storage device 56 to the controller 58. Basically, an acoustic transmission from the control device 14 may vibrate the transducer array 32, forming a voltage pulse that is conveyed to the switch 66. When the voltage exceeds a predetermined threshold, e.g., about a half volt (0.5 V), the switch 66 may close if previously in an open state, or open if previously in a closed state.
Further details regarding the structure and function of the power/communication unit 38 are disclosed in U.S. patent application Ser. No. 09/989,912, which has previously been incorporated herein by reference.
Referring to
The following description illustrates exemplary energy consumption parameters needed for the power/communication unit 138 to generate the proper amount of stimulation energy, and, consequently, exemplary power requirements for the acoustic transducer array 32. A single acoustic transducer cell 40 will typically generate 15 Pq/KPa at a frequency of approximately 40 KHz and a voltage of 10 V. The theoretical induced current at an acoustic pressure of 50 KPa will be 15 Pq/KPa×50 KPa×40 KHz=30 μA. Assuming a 50% AC to DC rectification efficiency, the practical induced current will be 15 μA. The resulting power will be 15 μA×10 V=0.15 mW. Assuming that twenty acoustic transducer cells 40 are connected in parallel, the total power generated by the transducer array 32 will be 20×0.15 mW=3 mW. A typical pacemaker has the following operational characteristics: amplitude of 2.5 V, frequency of 80 Hz, pulse width of 0.4 msec, and impedance of 1000 ohms. Thus, the power required by the acoustic stimulator 12 will be (2.5 V)2× 1/1000 ohms×80 Hz×4×10−4 sec=0.2 mW. As such, the implantable stimulator 12 (assuming 20 transducer cells 40) will generate 15 times the energy required for pacing the heart 18. The excess energy can be used to charge the energy storage device 56 to allow operation of the implantable stimulator 12 without acoustic excitation from the control device 14.
Referring to
Referring to
Referring to
Although the previously described implantable stimulator 12 is self-contained, thereby eliminating the need to implant and route external leads, other types of implantable stimulators can be used in the stimulation system 10 instead of the implantable stimulator 12. For example,
The control unit 76 comprises a casing 80 that is similar to the previously described casing 22, with the exception that the casing 80 is cylindrically shaped. The control unit 76 further comprises an acoustic transducer array 82 that is similar to the previously described transducer array 32, with the exception the transducer array 82 is circumferentially distributed around the cylindrical casing 80. The control unit 76 further comprises the previously described power/communication unit 84, which is suitably mounted within the casing 80. Since almost all of the componentry is located within the control unit 76, the stimulation electrode 74 can be made smaller, thereby facilitating delivery and implantation of the stimulation electrode 74 in the target region of the heart 18. The control unit 76 may be implanted in the chest region of the patient 16.
With particular reference to
The control device 14 further comprises memory 92 coupled to the controller 86, e.g., for storing commands, stimulation parameters, and/or data provided to the control device 14, as explained further below. The memory 92 may be a temporary buffer that holds data before transfer to another device, or non-volatile memory capable of storing the data substantially indefinitely, e.g., until extracted by the controller 86. For example, the memory 92 may be a memory card or an EPROM (not shown) built into the control device 14 or otherwise coupled to the controller 86. In the preferred embodiment, the implantable stimulator 12 may be operated in a “half-duplex” mode. In this mode, the implantable stimulator 12 can only either transmit or receive during any given time. To this end, the control device 14 comprises a transmitting/receiving (T/R) switch 94, which toggles the transducer 90 to alternately transmit and receive acoustic energy. Lastly, the control device 14 comprises a casing 96 for housing the previously described components.
As best illustrated in
The patch 15 may be formed from a flexible piezoelectric material, such as Polyvinylidene Fluoride (PVDF) or a PVDF copolymer. Such polymers may allow the patch 15 to produce ultrasonic waves, as well as allow the control device 14 to be secured to the patient's skin. Thus, the wall of the patch 15 itself may provide an acoustic transducer for the control device 14, i.e., for transmitting acoustic energy to and/or receiving acoustic energy from the implantable stimulator 12.
The patch 15 may then be secured to the patient's skin using a material, such as a layer of adhesive (not shown), substantially permanently affixed or otherwise provided on a surface of the patch 15. The adhesive may be hydrogel, silicon, polyurethane, polyethylene, polypropylene, fluorocarbon polymer, and the like. Alternatively, a separate adhesive may be applied to the patch 15 and/or to the patient's skin before applying the patch 15 in order to secure the control device 14 to the patient's skin. Such an adhesive may enhance acoustic coupling of the acoustic transducer(s) of the control device 14 to the patient's skin, and consequently to the implantable stimulator 12. Optionally, additional wetting material, including water, silicone oil, silicone gel, hydrogel, and the like, and/or other acoustically conductive material may be provided between the patch 15 or the acoustic transducer 90, and the patient's skin, e.g., to provide substantial continuity and minimize reflection or other losses and/or to secure the patch 15 to the patient 16.
The patch 15 may be relatively light and compact, for example, having a maximum surface dimension (e.g., width or height) not more than about ten to two hundred millimeters (10-200 mm), a thickness not more than about five to one hundred millimeters (5-100 mm), and a weight not more than about twenty to four hundred grams (20-400 g), such that the control device 14 may be inconspicuously attached to the patient. Thus, the patient 16 may be able to resume normal physical activity, without substantial impairment from the control device 14. Yet, the energy storage device 88 may be sufficiently large to communicate with the implantable stimulator 12 for an extended period of time, e.g., for hours or days, without requiring recharging or continuous coupling to a separate energy source.
Alternatively, the control device 14 may be carried by a belt (not shown) that may be secured around the patient, e.g., such that the acoustic transducer 90 is secured against the patient's skin. The belt may carry other components, e.g., an external power supply for the control device 14. For example, a battery pack (not shown) may be carried by the belt that may be coupled to the control device 14 for providing electrical energy for its operation. Alternatively, the control device 14 may take the form of a probe that is not worn by the patient 16, but rather can be selectively placed on the chest in order to communicate with the implantable stimulator 16.
Alternatively, a control device, similar to the previously described control device 14, may be implanted within the patient 16, e.g., the chest near the heart region. For example,
When used in conjunction with the implantable stimulator 12 having the power/communication unit 36 or power/communication unit 236 illustrated in respective
At the beginning of the energizing mode, the control device 14 determines the optimum frequency at which the implantable stimulator 12 should be energized. For example, the control device 14 may transmit broadband acoustic waves or scanning waves, i.e., scanning through a range of frequencies, and wait for the implantable stimulator 12 to respond. The implantable stimulator 12 may transmit acoustic waves at different frequencies in response to the diagnostic signal, and the control device 14 may determine the optimal frequency for communicating with the implantable stimulator 12 based upon the responses. For example, the control device 14 may repeatedly charge the implantable stimulator 12 using different frequency signals and measure the length of time that the implantable stimulator 12 is capable of transmitting data signals at each frequency to determine the optimal frequency. Alternatively, when the implantable stimulator 12 detects the signal, it may transmit a response at an optimal frequency that should be used to communicate with the implantable stimulator 12.
Once the control device 14 has determined the optimal frequency for communicating with the implantable stimulator 12 (or the control device 14 may already know the proper frequency to use), the control device 14 then transmits acoustic energizing waves 20 to the implantable stimulator 12, which are transformed and stored in the energy storage device 56 as electrical energy. The energy storage device 56 continues to store electrical energy until a predetermined voltage is achieved, e.g., about eight Volts (8 V), and then the controller 58 automatically disconnects the energy storage device 56 from the transducer array 32. After a predetermined time, e.g., between about five and sixty seconds (5-60 sec.), the control device 14 automatically ceases the energizing transmission. Alternatively, the control device 14 may cease energizing the implantable stimulator 12 by transmitting a stop command.
During the activation mode, the control device 14 transmits a command to the implantable stimulator 12 to close the switch 66, thereby placing the implantable stimulator 12 in the active mode. Once activated, the implantable stimulator 12 draws electrical energy from the energy storage device 56, and begins to transmit electrical energy to the stimulation electrode 34 in accordance with stimulation parameters, which may be previously stored in the memory 92 or may be transmitted from the control device 14 immediately after activation of the implantable stimulator 12. Alternatively, if no switch 66 is used, the control device 14 may transmit a start command to the implantable stimulator 12, which responds by transmitting electrical energy to the stimulation electrode 34.
The implantable stimulator 12 continues to stimulate the tissue until the control device 14 transmits a command to the implantable stimulator 12 to open the switch 66, thereby deactivating the implantable stimulator 12 and placing it in the dormant mode. Alternatively, if no switch 66 is used, the control device 14 may transmit a stop command to the implantable stimulator 12, which responds by ceasing transmission of the electrical energy to the stimulation electrode 34. Stimulation may also cease if the voltage of the energy storage device 56 falls below a predetermined threshold, e.g., below a level at which the stimulation electrode 34 may not continue to operate effectively, such as 1.5 volts. After the voltage falls below the predetermined threshold, the controller 58 may automatically discontinue operation of the implantable stimulator 12 by opening the switch 66 and returning to a dormant state until energized and activated by the control device 14.
Prior to, during, or subsequent to the activation mode, the control device 14 and implantable stimulator 12 may communicate additional information to each other. For example, the implantable stimulator 12 may transmit diagnostic information, which has been sensed by the optional sensor (not shown), to the control device 14. The control device 14 can then use this information to control the operation of the implantable stimulator 12. For example, the optional sensor can be a pressure sensor that can sense the blood flow through the heart chamber in which the implantable stimulator 12 is located. In this case, the implantable stimulator 12 can transmit pressure information to the control device 14. Alternatively, the pressure sensor may be even associated with another implantable device that is located in another region of the body, e.g., a pulmonary vein. The control device 14 may then respond to this pressure information by either activating or deactivating the implantable stimulator 12.
For example, if the pressure information indicates that the blood flow is below normal, the control device 14 may activate the implantable stimulator 12 by transmitting commands to close the switch 66, thereby initiating stimulation of the heart tissue. Once the diagnostic information indicates that the blood flow has been normal for a predetermined period of time, the control device 14 can then deactivate the implantable stimulator 12 by transmitting commands to open the switch 66, thereby ceasing stimulation of the heart tissue. This technique lends itself well to implantable cardioverter defibrillators (ICDs), which are designed to shock the heart when the blood pressure within the heart falls to a dangerous level. The control device 14 may alternatively or optionally use the diagnostic information to control the implantable stimulator 12 by controlling the parameters of the stimulation energy output by the implantable stimulator 12.
As another example for communicating information to each other, the control device 14 may transmit an identification code when transmitting commands to open or close the switch 66 in the implantable stimulator 12. In this manner, timing and sequence of the stimulation energy output from all of the implantable stimulators 12 can be controlled. Prior to placing the implantable stimulator 12 in the dormant mode, the controller 58 may transmit status information to the control device 14, e.g., an initial confirmation of instructions received from the control device 14, an identification code identifying the implantable stimulator 12, and/or a stop notice when stimulation is being discontinued by the controller 58.
As a safety measure against false positives (e.g., erroneous activation or deactivation), the control device 14 may acoustically transmit an initiation signal followed by a confirmation signal. When the implantable stimulator 12 receives these signals, the controller 58 may monitor the signals for a proper sequence, thereby ensuring that the switch 66 only closes upon receiving the proper initiation and confirmation signals. For example, the controller 58 may only acknowledge an activation signal that includes a first pulse followed by a second pulse separated by a predetermined delay. Use of a confirmation signal may be particularly important for certain applications, for example, to prevent unintentional stimulation of the heart 18.
In the case where the power/communication unit 138 illustrated in
In the case where the power/communication unit 238 illustrated in
In the case where the power/communication unit 338 illustrated in
Although particular embodiments of the present invention have been shown and described, it should be understood that the above discussion is not intended to limit the present invention to these embodiments. It will be obvious to those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the present invention. Thus, the present invention is intended to cover alternatives, modifications, and equivalents that may fall within the spirit and scope of the present invention as defined by the claims.
This application is a continuation of U.S. application Ser. No. 11/871,017, filed Oct. 11, 2007 (now U.S. Pat. No. 7,930,031), which is a continuation of U.S. application Ser. No. 10/632,265, filed Jul. 31, 2003 (now U.S. Pat. No. 7,283,874), which is a (1) a continuation-in-part of U.S. application Ser. No. 09/989,912, filed Nov. 19, 2001 (now U.S. Pat. No. 7,024,248), which is a continuation-in-part of U.S. application Ser. No. 09/690,615, filed Oct. 16, 2000 (now U.S. Pat. No. 6,628,989); (2) a continuation-in-part of U.S. application Ser. No. 09/888,272, filed Jun. 21, 2001 (now U.S. Pat. No. 6,764,446), which is a continuation-in-part of U.S. application Ser. No. 09/690,615, filed Oct. 16, 2000 (now U.S. Pat. No. 6,628,989); and (3) a continuation-in-part of U.S. patent application Ser. No. 10/413,428, filed Apr. 14, 2003 (now U.S. Pat. No. 7,198,603). All of these applications are expressly incorporated herein by reference in their entirety for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
2786899 | Carlislie et al. | Mar 1957 | A |
3536836 | Pfeiffer | Oct 1970 | A |
3672352 | Summers | Jun 1972 | A |
3757770 | Brayshaw et al. | Sep 1973 | A |
3805796 | Terry, Jr. et al. | Apr 1974 | A |
3853117 | Murr | Dec 1974 | A |
3943915 | Severson | Mar 1976 | A |
3970987 | Kolm | Jul 1976 | A |
4026276 | Chubbuck | May 1977 | A |
4041954 | Ohara | Aug 1977 | A |
4062354 | Taylor et al. | Dec 1977 | A |
4082097 | Mann et al. | Apr 1978 | A |
4099530 | Chen et al. | Jul 1978 | A |
4127110 | Bullara | Nov 1978 | A |
4170742 | Itagaki et al. | Oct 1979 | A |
4206761 | Cosman | Jun 1980 | A |
4206762 | Cosman | Jun 1980 | A |
4265252 | Chubbuck et al. | May 1981 | A |
4281666 | Cosman | Aug 1981 | A |
4281667 | Cosman | Aug 1981 | A |
4340038 | Mc Kean | Jul 1982 | A |
4354506 | Sakaguchi et al. | Oct 1982 | A |
4361153 | Slocum et al. | Nov 1982 | A |
4378809 | Cosman | Apr 1983 | A |
4385636 | Cosman | May 1983 | A |
4407296 | Anderson | Oct 1983 | A |
4471786 | Inagaki et al. | Sep 1984 | A |
4481950 | Duggan | Nov 1984 | A |
4494950 | Fischell | Jan 1985 | A |
4519401 | Ko et al. | May 1985 | A |
4556061 | Barreras et al. | Dec 1985 | A |
4593703 | Cosman | Jun 1986 | A |
4596255 | Snell et al. | Jun 1986 | A |
4614192 | Imran et al. | Sep 1986 | A |
4616640 | Kaali et al. | Oct 1986 | A |
4651740 | Schroeppel | Mar 1987 | A |
4653508 | Cosman | Mar 1987 | A |
4660568 | Cosman | Apr 1987 | A |
4676255 | Cosman | Jun 1987 | A |
4677985 | Bro et al. | Jul 1987 | A |
4708127 | Abdelghani | Nov 1987 | A |
4719919 | Marchosky et al. | Jan 1988 | A |
4791915 | Barsotti et al. | Dec 1988 | A |
4791936 | Snell et al. | Dec 1988 | A |
4793825 | Benjamin et al. | Dec 1988 | A |
4869251 | Lekholm et al. | Sep 1989 | A |
4885002 | Watanabe et al. | Dec 1989 | A |
4911217 | Dunn et al. | Mar 1990 | A |
4918736 | Bordewijk | Apr 1990 | A |
5074310 | Mick | Dec 1991 | A |
5113859 | Funke | May 1992 | A |
5117835 | Mick | Jun 1992 | A |
5160870 | Carson et al. | Nov 1992 | A |
5168869 | Chirife | Dec 1992 | A |
5184605 | Grzeszykowski | Feb 1993 | A |
5218861 | Brown et al. | Jun 1993 | A |
5279292 | Baumann et al. | Jan 1994 | A |
5291899 | Watanabe et al. | Mar 1994 | A |
5381067 | Greenstein et al. | Jan 1995 | A |
5423334 | Jordan | Jun 1995 | A |
5433736 | Nilsson | Jul 1995 | A |
5445150 | Dumoulin et al. | Aug 1995 | A |
5495453 | Wociechowski et al. | Feb 1996 | A |
5562621 | Claude et al. | Oct 1996 | A |
5619997 | Kaplan | Apr 1997 | A |
5620475 | Magnusson | Apr 1997 | A |
5704352 | Tremblay et al. | Jan 1998 | A |
5704366 | Tacklind et al. | Jan 1998 | A |
5712917 | Offutt | Jan 1998 | A |
5721886 | Miller | Feb 1998 | A |
5724985 | Snell et al. | Mar 1998 | A |
5743267 | Nikolic et al. | Apr 1998 | A |
5749909 | Schroeppel et al. | May 1998 | A |
5757104 | Getman et al. | May 1998 | A |
5759199 | Snell et al. | Jun 1998 | A |
5800478 | Chen et al. | Sep 1998 | A |
5807258 | Cimochowski et al. | Sep 1998 | A |
5814089 | Stokes et al. | Sep 1998 | A |
5833603 | Kovacs et al. | Nov 1998 | A |
5861018 | Feierbach | Jan 1999 | A |
5891180 | Greeninger et al. | Apr 1999 | A |
5904708 | Goedeke | May 1999 | A |
5925001 | Hoyt et al. | Jul 1999 | A |
5935078 | Feierbach | Aug 1999 | A |
5957861 | Combs et al. | Sep 1999 | A |
5967989 | Cimochowski et al. | Oct 1999 | A |
6015387 | Schwartz et al. | Jan 2000 | A |
6030374 | McDaniel | Feb 2000 | A |
6070103 | Ogden | May 2000 | A |
6140740 | Porat et al. | Oct 2000 | A |
6141588 | Cox | Oct 2000 | A |
6162238 | Kaplan et al. | Dec 2000 | A |
6164284 | Schulman et al. | Dec 2000 | A |
6167303 | Thompson | Dec 2000 | A |
6170488 | Spillman, Jr. et al. | Jan 2001 | B1 |
6176840 | Nishimura et al. | Jan 2001 | B1 |
6183426 | Akisada et al. | Feb 2001 | B1 |
6185452 | Schulman et al. | Feb 2001 | B1 |
6185454 | Thompson | Feb 2001 | B1 |
6185460 | Thompson | Feb 2001 | B1 |
6198963 | Haim et al. | Mar 2001 | B1 |
6198965 | Penner et al. | Mar 2001 | B1 |
6198971 | Leysieffer | Mar 2001 | B1 |
6200265 | Walsh et al. | Mar 2001 | B1 |
6236889 | Soykan et al. | May 2001 | B1 |
6237398 | Porat et al. | May 2001 | B1 |
6248080 | Miesel et al. | Jun 2001 | B1 |
6259951 | Kuzma et al. | Jul 2001 | B1 |
6260152 | Cole et al. | Jul 2001 | B1 |
6261249 | Tallish et al. | Jul 2001 | B1 |
6277078 | Porat et al. | Aug 2001 | B1 |
6315721 | Schulman et al. | Nov 2001 | B2 |
6427088 | Bowman et al. | Jul 2002 | B1 |
6431175 | Penner et al. | Aug 2002 | B1 |
6432050 | Porat et al. | Aug 2002 | B1 |
6442413 | Silver | Aug 2002 | B1 |
6442433 | Linberg | Aug 2002 | B1 |
6472991 | Schulman et al. | Oct 2002 | B1 |
6473638 | Ferek-Petric | Oct 2002 | B2 |
6564807 | Schulman et al. | May 2003 | B1 |
6577899 | Lebel et al. | Jun 2003 | B2 |
6584352 | Combs et al. | Jun 2003 | B2 |
6607485 | Bardy | Aug 2003 | B2 |
6628989 | Penner et al. | Sep 2003 | B1 |
6644322 | Webb | Nov 2003 | B2 |
6664763 | Echarri et al. | Dec 2003 | B2 |
6671552 | Merritt et al. | Dec 2003 | B2 |
6676601 | Lacoste et al. | Jan 2004 | B1 |
6689091 | Bui et al. | Feb 2004 | B2 |
6712772 | Cohen et al. | Mar 2004 | B2 |
6731976 | Penn et al. | May 2004 | B2 |
6735532 | Freed et al. | May 2004 | B2 |
6754538 | Linberg | Jun 2004 | B2 |
6764446 | Wolinsky et al. | Jul 2004 | B2 |
6788973 | Davis et al. | Sep 2004 | B2 |
6790187 | Thompson et al. | Sep 2004 | B2 |
6799280 | Edenfield et al. | Sep 2004 | B1 |
6804557 | Kroll | Oct 2004 | B1 |
6826430 | Faltys et al. | Nov 2004 | B2 |
6855115 | Fonseca et al. | Feb 2005 | B2 |
6873869 | Fischer | Mar 2005 | B2 |
6960801 | Lung | Nov 2005 | B2 |
6970037 | Sakhuja et al. | Nov 2005 | B2 |
6978181 | Snell | Dec 2005 | B1 |
6985088 | Goetz et al. | Jan 2006 | B2 |
6985773 | Von Arx et al. | Jan 2006 | B2 |
6988215 | Splett et al. | Jan 2006 | B2 |
6993393 | Von Arx et al. | Jan 2006 | B2 |
7003349 | Andersson et al. | Feb 2006 | B1 |
7013178 | Reinke et al. | Mar 2006 | B2 |
7024248 | Penner et al. | Apr 2006 | B2 |
7027871 | Burnes et al. | Apr 2006 | B2 |
7027872 | Thompson | Apr 2006 | B2 |
7035684 | Lee | Apr 2006 | B2 |
7060030 | Von Arx et al. | Jun 2006 | B2 |
7061381 | Forcier et al. | Jun 2006 | B2 |
7082334 | Boute et al. | Jul 2006 | B2 |
7096068 | Mass et al. | Aug 2006 | B2 |
7123964 | Betzold et al. | Oct 2006 | B2 |
7198603 | Penner et al. | Apr 2007 | B2 |
7203551 | Houben et al. | Apr 2007 | B2 |
7209790 | Thompson et al. | Apr 2007 | B2 |
7212133 | Goetz et al. | May 2007 | B2 |
7236821 | Cates et al. | Jun 2007 | B2 |
7273457 | Penner et al. | Sep 2007 | B2 |
7283874 | Penner et al. | Oct 2007 | B2 |
7286872 | Kramer et al. | Oct 2007 | B2 |
7319903 | Bange et al. | Jan 2008 | B2 |
7335161 | Von Arx et al. | Feb 2008 | B2 |
7353063 | Simms, Jr. | Apr 2008 | B2 |
7469161 | Gandhi et al. | Dec 2008 | B1 |
7479108 | Rini et al. | Jan 2009 | B2 |
7617001 | Penner et al. | Nov 2009 | B2 |
7650185 | Maile et al. | Jan 2010 | B2 |
7756587 | Penner et al. | Jul 2010 | B2 |
7930031 | Penner | Apr 2011 | B2 |
20010025139 | Pearlman | Sep 2001 | A1 |
20020065540 | Lebel et al. | May 2002 | A1 |
20020077673 | Penner et al. | Jun 2002 | A1 |
20020151770 | Noll, III et al. | Oct 2002 | A1 |
20030114897 | Von Arx et al. | Jun 2003 | A1 |
20030212441 | Starkweather et al. | Nov 2003 | A1 |
20040039424 | Merritt et al. | Feb 2004 | A1 |
20040133092 | Kain | Jul 2004 | A1 |
20040152999 | Cohen et al. | Aug 2004 | A1 |
20040172083 | Penner | Sep 2004 | A1 |
20040210141 | Miller | Oct 2004 | A1 |
20050113705 | Fischell et al. | May 2005 | A1 |
20050136385 | Mann et al. | Jun 2005 | A1 |
20050159785 | Rueter | Jul 2005 | A1 |
20050159789 | Brockway et al. | Jul 2005 | A1 |
20050177097 | Hildebrand et al. | Aug 2005 | A1 |
20050203444 | Schonenberger et al. | Sep 2005 | A1 |
20050288727 | Penner | Dec 2005 | A1 |
20060009818 | Von Arx et al. | Jan 2006 | A1 |
20060020307 | Davis et al. | Jan 2006 | A1 |
20060025834 | Von Arx et al. | Feb 2006 | A1 |
20060031378 | Vallapureddy et al. | Feb 2006 | A1 |
20060041287 | Dewing et al. | Feb 2006 | A1 |
20060041288 | Dewing et al. | Feb 2006 | A1 |
20060058627 | Flaherty et al. | Mar 2006 | A1 |
20060064134 | Mazar et al. | Mar 2006 | A1 |
20060064135 | Brockway | Mar 2006 | A1 |
20060064142 | Chavan et al. | Mar 2006 | A1 |
20060085039 | Hastings et al. | Apr 2006 | A1 |
20060122667 | Chavan et al. | Jun 2006 | A1 |
20060142819 | Penner et al. | Jun 2006 | A1 |
20060149329 | Penner | Jul 2006 | A1 |
20070010742 | Torp et al. | Jan 2007 | A1 |
20070055313 | Stahmann et al. | Mar 2007 | A1 |
20070142728 | Penner et al. | Jun 2007 | A1 |
20070150014 | Kramer et al. | Jun 2007 | A1 |
20070162090 | Penner | Jul 2007 | A1 |
20070179549 | Russie | Aug 2007 | A1 |
20070250126 | Maile et al. | Oct 2007 | A1 |
20080015421 | Penner | Jan 2008 | A1 |
20080071178 | Greenland et al. | Mar 2008 | A1 |
20080103553 | Penner et al. | May 2008 | A1 |
20080108915 | Penner | May 2008 | A1 |
20080171941 | Huelskamp et al. | Jul 2008 | A1 |
20080195002 | Thompson et al. | Aug 2008 | A1 |
20080243210 | Doron et al. | Oct 2008 | A1 |
20090312650 | Maile et al. | Dec 2009 | A1 |
20090326609 | Doron | Dec 2009 | A1 |
20100023091 | Stahmann et al. | Jan 2010 | A1 |
20100106028 | Penner et al. | Apr 2010 | A1 |
Number | Date | Country |
---|---|---|
0 499 939 | Aug 1992 | EP |
0 928 598 | Dec 1998 | EP |
1962557 | Aug 2008 | EP |
10-505529 | Jun 1998 | JP |
2002-515807 | May 2002 | JP |
2004-041724 | Feb 2004 | JP |
2004-511313 | Apr 2004 | JP |
2004-537347 | Dec 2004 | JP |
2005-521528 | Jul 2005 | JP |
WO8802250 | Apr 1988 | WO |
WO9626673 | Sep 1996 | WO |
WO9843338 | Oct 1998 | WO |
WO 9843701 | Oct 1998 | WO |
WO9934453 | Jul 1999 | WO |
WO0047109 | Aug 2000 | WO |
WO0128627 | Apr 2001 | WO |
WO0174278 | Oct 2001 | WO |
WO 01-76687 | Oct 2001 | WO |
WO0197907 | Dec 2001 | WO |
WO0203347 | Jan 2002 | WO |
WO0232502 | Apr 2002 | WO |
WO02089904 | Nov 2002 | WO |
WO03002243 | Jan 2003 | WO |
WO03043688 | May 2003 | WO |
WO03096889 | Nov 2003 | WO |
WO 2004-089465 | Oct 2004 | WO |
WO2005009535 | Feb 2005 | WO |
WO2005053786 | Jun 2005 | WO |
WO 2005-099816 | Oct 2005 | WO |
WO 2006-017615 | Feb 2006 | WO |
WO 2006-034183 | Mar 2006 | WO |
WO2006060668 | Jun 2006 | WO |
WO 2006126401 | Nov 2006 | WO |
WO2007070794 | Jun 2007 | WO |
WO2007080487 | Jul 2007 | WO |
WO2007127696 | Nov 2007 | WO |
WO2008118908 | Oct 2008 | WO |
Entry |
---|
Harrison et al., “A Low-Power Low-Noise CMOS Amplifier for Neural Recording Applications,” IEEE Journal of Solid-State Circuits 38(6):958-965, Jun. 2003. |
IEEE Transactions on Biomedical Engineering, vol. 42, No. 5, May 1995, Title: Data Transmission from an Implantable Biotelemeter by Load-Shift Keying Using Circuit Configuration Modulator, by Zhengnian Tang, Brian Smith, John H. Schild, and P. Hunter Peckham, pp. 524-528. |
Ishiwara et al., “Current Status and Prospects of FET-Type Ferroelectric Memories,” Journal of Semiconductor Technology and Science 1(1): 1-14, Mar. 2001. |
Neurosurgery Clinics of North America vol. 4, No. 4, Oct. 1993, Hydrocephalus, Title: The Treatment of Hydrocephalus by Paul M. Kanev, MD, and T.S. Park, MD., pp. 611-619. |
Neurosurgery Clinics of North America, vol. 4, No. 4, Oct. 1993, Hydrocephalus, Title: Complications in Ventricular Cerebrospinal Fluid Shunting by Jeffrey P. Blount, MD, John A. Campbell, MD, and Stephen J. Haines, MD, pp. 633-656. |
Neurosurgery Update II Vascular, Spinal, Pediatric, and Functional Neurosurgery, Published by McGraw-Hill, Inc., 1991, Editors Robert H. Wilkins, M.D., and Setti S. Rengachary, M.D., Title Shunt Complications by R. Michael Scott, pp. 300-319. |
Neurosurgery, vol. 34, No. 5, May 1994, Concepts and Innovations, Title: A New Ventricular Catheter for the Prevention and Treatment of Proximal Obstruction in Cerebrospinal Fluid Shunts, by Enrique C.G. Ventureyra, M.D., F.R.C.S.(C)., F.A.C.S., Michael J. Higgins, M.D., pp. 924-926. |
Neurosurgery, vol. 34, No. 6, Jun. 1994, Rapid Communication, Title: The Use of the Codman-Medos Programmable Hakim Valve in the Management of Patients with Hydroceplhalus: Illustrative Cases, by Peter McL. Black, M.D., Ph.D., Rodolfo Hakim, M.D., Nancy Olsen Bailey, R.N., B.S.N., M.B.A., pp. 1110-1113. |
Pediatric Neurosurgery 2nd Edition, Surgery of the Developing Nervous System, Published by W.B. Saunders Company Harcourt Brace Jovanovich, Inc., 1989. Title: Treatment of Hydrocephalus by Harold L. Rekate, M.D.; Ventricular Shunts: Complications and Results by Robert L. McLaurin, M.D.; pp. 200-229. |
International Search Report and Written Opinion issued in PCT/US2009/062019, 14 pages, Apr. 12, 2010. |
Extended European Search Report issued in EP 10184174, mailed Dec. 7, 2010. |
Number | Date | Country | |
---|---|---|---|
20110160804 A1 | Jun 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11871017 | Oct 2007 | US |
Child | 13046083 | US | |
Parent | 10632265 | Jul 2003 | US |
Child | 11871017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09989912 | Nov 2001 | US |
Child | 10632265 | US | |
Parent | 09690615 | Oct 2000 | US |
Child | 09989912 | US | |
Parent | 09888272 | Jun 2001 | US |
Child | 10632265 | US | |
Parent | 09690615 | US | |
Child | 09888272 | US | |
Parent | 10413428 | Apr 2003 | US |
Child | 10632265 | US |